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Background: Conventional Sanger sequencing reliably detects the majority of genetic mutations associated with
hereditary cancers, such as single-base changes and small insertions or deletions. However, detection of genomic
rearrangements, such as large deletions and duplications, requires special technologies. Microarray analysis has been
successfully used to detect large rearrangements (LRs) in genetic disorders.
Methods: We designed and validated a high-density oligonucleotide microarray for the detection of gene-level
genomic rearrangements associated with hereditary breast and ovarian cancer (HBOC), Lynch, and polyposis
syndromes. The microarray consisted of probes corresponding to the exons and flanking introns of BRCA1 and
BRCA2 (≈1,700) and Lynch syndrome/polyposis genes MLH1, MSH2, MSH6, APC, MUTYH, and EPCAM (≈2,200). We
validated the microarray with 990 samples previously tested for LR status in BRCA1, BRCA2, MLH1, MSH2, MSH6, APC,
MUTYH, or EPCAM. Microarray results were 100% concordant with previous results in the validation studies.
Subsequently, clinical microarray analysis was performed on samples from patients with a high likelihood of HBOC
mutations (13,124), Lynch syndrome mutations (18,498), and polyposis syndrome mutations (2,739) to determine
the proportion of LRs.
Results: Our results demonstrate that LRs constitute a substantial proportion of genetic mutations found in patients
referred for hereditary cancer genetic testing.
Conclusion: The use of microarray comparative genomic hybridization (CGH) for the detection of LRs is well-suited
as an adjunct technology for both single syndrome (by Sanger sequencing analysis) and extended gene panel
testing by next generation sequencing analysis. Genetic testing strategies using microarray analysis will help identify
additional patients carrying LRs, who are predisposed to various hereditary cancers.
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Sequencing and large rearrangement (LR) analyses detect
DNA changes within hereditary cancer genes and are of-
fered to individuals with a personal and/or family history
of cancer to identify pathogenic mutation carriers. For
example, patients with pathogenic mutations in BRCA1 or
BRCA2 have a diagnosis of hereditary breast and ovarian
cancer syndrome (HBOC), a condition for which there are
extensive medical management guidelines aimed at the
prevention and early detection of breast and ovarian
cancer. Lynch syndrome is the most common inherited
colorectal cancer (CRC) syndrome and is associated with
mutations in DNA mismatch repair (MMR) genes, mainly
MLH1 and MSH2, but also MSH6, PMS2, and EPCAM
[1]. In addition, there is an increased risk for colorectal
cancer associated with mutations in the APC (familial
adenomatous polyposis [FAP] or attenuated-FAP) and
MUTYH (MUTYH-associated polyposis) genes. Screening
is important for genetic counseling in affected families
and for early diagnosis or disease prevention in carriers.
Early identification of mutation carriers allows for in-
creased clinical surveillance and early detection, and may
prompt more aggressive prevention strategies, such as
prophylactic surgery or chemoprevention, to reduce risk.
Conventional Sanger sequencing detects the majority of
germline mutations associated with hereditary cancers,
which consist primarily of nonsense, missense, small in/del
and splice-site mutations. However, conventional Sanger
sequencing cannot detect certain classes of genetic alter-
ations, including single- and multi-exonic genomic re-
arrangements such as deletions and duplications. Such
genomic rearrangements account for a clinically significant
proportion of the common hereditary cancer syndromes.
For instance, genomic rearrangements, primarily deletions,
account for 5-30% and 10-60% of all MLH1 and MSH2
pathogenic germline alterations, respectively, in Lynch
syndrome families; the wide range of frequencies is a
result of small sample populations in most studies [2-9].
Baudhuin et al. utilized both Southern blotting and MLPA
techniques in a consecutive series of 365 unrelated cases
and found that, although the majority of pathogenic muta-
tions identified in MLH1 and MSH2 were point mutations
and small insertions/deletions, large genomic alterations
were present in 17.9% and 45.3% of the MLH1 and MSH2
mutation-positive carriers, respectively [10]. Large geno-
mic rearrangements in BRCA1 and BRCA2 account for a
low but persistent percentage of all BRCA1 and BRCA2
alterations [11,12]. Genomic rearrangements of BRCA1
appear to be more prevalent than BRCA2 genomic rear-
rangements [13].
A variety of molecular genetic techniques can be used
to detect genomic rearrangements in individuals sus-
pected of a hereditary cancer syndrome, including multi-
plex quantitative PCR, MLPA, and Southern blotting.The sequencing of the human genome and the develop-
ment of high-throughput methods of robotically arraying
genetic material on a solid substrate have led to the
development of genomic microarrays [14,15], which
represent the integration of traditional and molecular
cytogenetic techniques and enable the clinical diagnosis
of chromosomal abnormalities at an unprecedented reso-
lution. Microarrays comprise thousands of discrete seg-
ments of DNA, or probes, selected from genomic regions
of interest, from intervals throughout the genome. Micro-
array analysis has been successfully used to detect changes
in DNA copy number in genetic disorders associated with
congenital anomalies and in solid tumors [16-18]. Several
studies have used microarrays for the identification of
genomic rearrangements associated with common here-
ditary cancer syndromes in a research setting [19,20].
Staaf et al. designed a custom oligonucleotide microarray
for the characterization of genomic rearrangements of
BRCA1, BRCA2, MLH1, and MSH2. The microarray re-
sults were concordant with MLPA in 26/30 cases; four
discrepancies were the result of inaccurate MLPA results.
In this study, we describe the design and validation of
an oligonucleotide-based microarray targeted to genes
associated with hereditary cancer. Microarray analysis of
patients referred to our laboratory for LR testing in con-
junction with sequencing analysis demonstrates that LRs
represent a substantial proportion of genetic mutations
identified in the clinical laboratory. It should be noted
that an increasing number of laboratories have integra-
ted the use of next generation sequencing (NGS) tech-
nology for the detection of mutations in panels of genes.
Though NGS is a proven technology for the accurate de-
tection of sequencing mutations, detection of LRs by
NGS remains challenging [21]. Until we achieve accurate
and reliable LR detection by NGS, microarray CGH will
remain a viable transitional tool for the detection of LRs
for both single syndrome and extended panel testing.
Materials and methods
Microarray design
Our laboratory developed a high-density oligonucleotide
microarray consisting of approximately 1,700 overlapping
probes corresponding to exons and flanking introns of
BRCA1 and BRCA2. Approximately 2200 overlapping
probes correspond to exons and flanking introns of
MLH1, MSH2, MSH6, APC, and MUTYH, and exons 2, 3,
8, 9, and the 3’ UTR of EPCAM. On average, each base of
every gene on the microarray has 2.5x or greater probe
coverage. The probes (≈45-60 bases) are tiled to ensure
detection of rearrangements that are as small as a few
hundred bases in length. In addition, probes were selected
to overlap flanking regions of repetitive sequence (e.g.
guanine cytosine (GC)-rich regions). A stringent selection
process was used to create an optimal probe set. The
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known negative and positive samples to produce a micro-
array CGH assay with enhanced sensitivity and specificity
to detect variations in dosage.
Microarray analysis
Genomic DNA was labeled with Cy3 & Cy5 dyes using an
Enzymatic Labeling Kit (Agilent Technologies, Santa
Clara, CA) according to manufacturer’s instructions.
Array hybridization and washing were performed on
custom Agilent 8×15k arrays (Agilent Technologies), and
arrays were scanned using a High Resolution Microarray
Scanner (Agilent Technologies). Analysis of the micro-
array data was performed in two steps. First, a proprietary
software prediction program predicted the likelihood of a
particular result for a given sample. Specifically, the pre-
diction algorithm examined a window of contiguous
probes, a defined subset of which must have had increased
or decreased copy number to generate a positive call. Soli-
tary probes that deviated from the baseline did not trigger
a positive call by the algorithm. The software analysis was
accompanied by visual review of the data.
Briefly, the average ratio (Cy5:Cy3) of fluorescent in-
tensity obtained from cohybridized test and reference
DNA for each probe was calculated and normalized. In
addition to the normalizations carried out by Agilent’s
Feature Extraction, each probe is also normalized based
on GC-content. This normalization is not necessary if all
probes designed fall within tight GC-content criteria but
this would not allow for tiling coverage across many
genes. This normalization works by compensating for
dosage biases introduced by dye normalization in probes
based on their GC-content and signal intensity dif-
ference of the Cy3 and Cy5 labeled probes. The average
ratios of the fluorescent intensities for each case were
converted to a log2 scale and plotted using our propri-
etary software. This software normalizes each probe
based on the historic performance of that probe to mi-
nimize biases attributable to the test rather than the pa-
tient sample. The theoretical log2 conversions for ratios
(test/reference) of 1/2, 2/2, and 3/2 are approximately −1,
0, and 0.58 respectively. In practice, the actual values
never reach their theoretical limits. For single-copy losses
(1/2) and single-copy gains (3/2), we used thresholds of
approximately −0.5 and 0.29, respectively; deletions are
typically visualized as probe clusters that center within
the −0.5 to −1.0 amplitude lines. A cluster of probes cen-
tered between the 0.29 to 0.58 amplitude lines represents
a duplication.
Microarray validation study
To validate the microarray we performed microarray
analysis on samples that were previously identified to be
positive or negative for a LR in BRCA1, BRCA2, MLH1,MSH2, MSH6, EPCAM, APC, and MUTYH by multiplex
quantitative PCR, MLPA, Southern blotting or long-
range PCR. An additional synthetic control using geno-
mic DNA digested with restriction enzymes was also
used to assess MUTYH.
Clinical testing for LRs by microarray analysis
To examine the proportion of LRs among genetic mu-
tations identified by a large clinical laboratory, we
performed microarray analysis on patients referred to
Myriad Genetic Laboratories, Inc., for clinical testing of
BRCA1 and BRCA2 (May 2012 to November 2013) or
MLH1, MSH2, MSH6, EPCAM, and/or APC (September
2012 to November 2013). All patient data regarding cli-
nical history and ancestry were obtained by health care
provider report on test requisition forms. For each pa-
tient population, data were analyzed for patients who
met clinical criteria predicting a relatively high proba-
bility of carrying a mutation in BRCA1 or BRCA2
(HBOC), MLH1, MSH2, MSH6 or EPCAM (Lynch syn-
drome) or APC (polyposis). These patients received LR
analysis concurrent with sequencing analysis. Patients




We initially validated the microarray assay for hereditary
colorectal cancer genes with a blinded analysis of 357 pre-
viously tested DNA samples derived from patients with a
personal or family history of CRC, of which 264 were
extracted from blood and 93 from buccal samples. We
correctly identified all 88 positives among 357 samples
that were previously examined for deletions and duplica-
tions in MLH1, MSH2, MSH6, and the 3’ terminal region
of EPCAM by multiplex quantitative PCR and/or MLPA.
We also correctly identified all 7 positive samples among
307 that were previously tested for the presence of LRs in
APC by Southern blot and MLPA. We correctly identified
a homozygous MUTYH deletion previously detected by
sequencing and confirmed by long-range PCR, as well as a
synthetic positive control sample tested in replicates.
We next validated the microarray by blinded analysis of
DNA samples previously examined for LR mutations in
BRCA1 and BRCA2 using our clinically validated multi-
plex quantitative PCR assay. The microarray validation
was carried out in two phases and tested a total of 633
DNA samples. The second phase of validation incorpo-
rated minor enhancements for process efficiency that did
not affect test sensitivity or specificity. The DNA samples
examined for LRs were extracted from 317 peripheral
blood and 316 buccal mouthwash specimens. Forty-two of
the blood samples and 38 of the buccal samples were posi-
tive for a LR. Results for all 633 DNA samples were 100%
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PCR result. In addition, these validation studies correctly
identified two instances of an Alu insertion in BRCA2
specific to the Portuguese population (c.156_157insAlu).
The microarray assay for BRCA1, BRCA2, MLH1, MSH2,
MSH6, EPCAM, APC, and MUTYH was validated against
a collective total of 990 DNA samples that were previously
characterized for LRs with 100% concordance.
Performance of microarray in the clinical setting
Once validated, we performed microarray analysis on
samples from patients referred for HBOC (13,124), Lynch
syndrome (18,498), and polyposis syndrome (2,739)
testing. All samples received LR analysis by microarray
concurrent with sequencing analysis. Among all Lynch
syndrome deleterious and suspected deleterious mutations
detected, 17.2% (189/1,098) were LRs in MLH1, MSH2,
MSH6, or EPCAM compared with 82.8% (909/1,098) se-
quencing mutations inMLH1,MSH2, andMSH6 (Table 1).
Deletions in the 3’ terminal region of EPCAM that affect
expression of the adjacent MSH2 gene (but not EPCAM
point mutations) are associated with Lynch syndrome
[22,23]. Of the LRs detected, 27.0% (51/189) were in
MLH1, 57.7% (109/189) in MSH2, 5.3% (10/189) in
MSH6, and 4.2% (8/189) in the 3’ terminal region of
EPCAM alone. Deletions in both MSH2 and the 3’ter-
minal region of EPCAM comprised 5.8% (11/189) of the
LRs. Collectively, 92.1% (174/189) of the LRs were dele-
tions and 7.9% (15/189) were duplications within MLH1,
MSH2, MSH6, and EPCAM.
Among all APC deleterious and suspected deleterious
mutations detected, 9.6% (31/324) were LRs while 90.4%
(293/324) were sequencing mutations. Of the LRs de-
tected in APC, 93.5% (29/31) were deletions and 6.5%
(2/31) were duplications.
Of suspected HBOC samples tested, 1.4% (185/13,124)
had a LR mutation in BRCA1 or BRCA2. Of all HBOC
deleterious or suspected deleterious mutations in BRCA1
or BRCA2, 8.5% (185/2186) of mutations were LRs andTable 1 Clinical testing summary
Syndrome Gene(s) tested Patients testeda Total
and L
HBOC BRCA1 13,124 2,186
BRCA2





Polyposis APC 2,739 324
aSequencing and rearrangement testing done concurrently.91.5% (2001/2186) were sequencing mutations. Collectively,
76.8% (142/185) of mutations were deletions and 23.2%
(43/185) were duplications/triplications within BRCA1and
BRCA2.
Discussion
We performed targeted microarray analysis concurrent
with Sanger sequencing analysis on a large clinical cohort
of samples with a high likelihood of HBOC or hereditary
CRC mutations and showed that 17.2% of mutations in
Lynch syndrome samples, 9.6% of mutations in polyposis
samples, and 8.5% of mutations in HBOC samples were
LRs. These results demonstrate that LRs constitute a sub-
stantial proportion of genetic mutations associated with a
common hereditary cancer syndrome identified by a large
clinical laboratory.
The primary advantage of targeted CGH-based micro-
array analysis is the ability to simultaneously detect exon-
level dosage alterations of multiple genes represented on
the array. In addition, microarrays have several advantages
over other commonly used molecular techniques such
as Southern blotting and MLPA. Southern blotting has
several limitations: it is time-consuming, expensive and
requires a large amount of DNA. MLPA is a relatively in-
expensive, simple and reproducible PCR-based method
that uses the same equipment used for DNA sequencing
[4,24]. MLPA is commonly used for the detection of ge-
nomic rearrangements in genes such as BRCA1 and
BRCA2 [25,26]. However, MLPA has several limitations.
Sequence variants in probe binding sites can yield false-
positive results; conversely, limited probe coverage across
genes may produce false-negative results. Technical arti-
facts often necessitate confirmatory studies, further in-
creasing cost, resources, and turnaround time. Compared
to high-density microarrays, MLPA provides limited infor-
mation regarding the location of the deletion or du-
plication breakpoints in the affected flanking/intronic
regions, which may lead to laborious mapping for se-
quence characterization of the rearrangements. Mostpositive sequence
R mutations
Total LR
(% of positive mutations)
LR by gene
(% of LR)
185 (8.5%) 167 (90.3%)
18 (9.7%)





31 (9.6%) 31 (100%)
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one or a few genes at a time. The requirement for manual
processing further increases sample turnaround time and
prohibits high-throughput applications, which are crucial
for high-volume sample processing in large clinical labora-
tories. MLPA also has the potential to miss some partial
deletions or duplications. Figure 1 illustrates the extent of
probe coverage for MSH2 exon 10 in our targeted micro-
array assay. The MLPA assay did not detect this deletion
because the single MLPA probe hybridizes to a region of
MSH2 intron 10, which is not deleted. A typical MLPA
assay will have 1–2 probes per exon, depending on the
size of that exon. Thus, any dosage changes that alter a
part of the exon not covered by the MLPA probe will not
be detected. Furthermore, it is notable that our targeted
microarray probe coverage extends into the binding sites
for our sequencing primers, as depicted in Figure 1. In this
way, we are able to detect deletions that remove sequen-
cing primer binding sites and lead to mono-allelic sequen-
cing results.
Figure 2 shows the actual partial deletion of exon 10
in MSH2 in one of our patients, detected by microarray
analysis. The microarray showed a loss of probes span-
ning part of the exon. Confirmatory long-range PCR and
sequencing analysis demonstrated that the deletion re-
moved approximately 2,000 base pairs (bp) of sequence
(data not shown).
Microarray-CGH is less prone to technical artifacts
and is amenable to automation, which allows microarray
to be utilized as a high-throughput assay that can de-
crease sample turnaround times and costs. Microarrays
are also scalable—probes can easily be added to current
areas of interest and additional syndromes/genes can be
added at little additional cost to the laboratory. Targeted
microarray CGH therefore provides yet another advan-
tage over other LR detection methodologies. MicroarrayFigure 1 Diagrammatic representation of the 1900 bp deletion that s
10. This figure maps the locations of multiple overlapping microarray prob
(MRC-Holland, P003-C1) has only one MLPA probe in intron 10. The locatio
probes that cover these regions are also depicted.can be easily adapted for use as an adjunct for panel
analysis by NGS, allowing the laboratory to evaluate the
LR status of multiple genes at once.
Because microarrays are designed to detect gains and
losses in dosage at a specific locus, insertions of material
from elsewhere in the genome, particularly of repetitive
sequence elements, are difficult to detect. However, our
results suggest insertions occur infrequently. To date, the
most common of all known insertions found in BRCA1
and BRCA2 is an Alu insertion that integrates within nu-
cleotides 156 and 157 in exon 3 of the BRCA2 gene
(c.156_157insAlu). This has been reported as a founder
mutation in the Portuguese population. We have specific-
ally designed probes on our microarray assay to screen for
the Portuguese founder mutation. We have included
probes specific to the native BRCA2 region in exon 3 that
would be disrupted by the insertion as well as other
probes that hybridize to the Alu inserted sequence. For
this latter probe set, one half of the probe hybridizes to
the native BRCA2 exon 3 sequence and the other half
hybridizes to the first 30 bases of the inserted sequence.
Together, this collection of probes functions as a scree-
ning tool to flag samples that potentially carry the
Portuguese insertion. We confirm the presence of the in-
sertion using a targeted breakpoint-specific PCR assay.
During the study period, we identified only three cases of
the BRCA2 (c.156_157insAlu) founder mutation in 13,124
clinical samples tested.
Finally, microarrays are not reliant on clinical suspi-
cion of a specific condition. They provide an objective,
comprehensive means of genetic diagnosis. In particular,
Lynch syndrome can be the most challenging hereditary
CRC syndrome to recognize because of the absence of
an overt polyposis phenotype, and there are many pa-
tients with Lynch syndrome who remain undiagnosed.
Testing strategies such as microarray analysis thattarts in intron 9 of MSH2 and removes the first 94 bases of exon
es that can assess for LRs in this region. The MLH1/MSH2 MLPA kit
ns of the forward and reverse sequencing primers and the microarray
Figure 2 Targeted microarray result demonstrating a partial deletion of exon 10 in MSH2 at the A) gene level and B) probe level.
Vertical yellow lines represent MSH2 exons. Individual probes are represented by the black dots. Probe clusters for exons devoid of LRs are shown
to center at the 0 horizontal line, which represents two allelic copies. The cluster of microarray probes spanning the 5’ portion of MSH2 exon 10
probe centers at approximately −0.75, indicating the presence of a partial deletion of this exon.
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a hereditary cancer syndrome, particularly those for
whom sequencing analysis was negative.
The ability to analyze multiple genes simultaneously
facilitates this shift away from single-locus genetic test-
ing toward panel testing of multiple genes of interest.
With the advent of NGS, our laboratory and others are
working towards adapting this technology for the detec-
tion of LRs as well.
Conclusion
At present, we have validated the clinical use of micro-
array CGH to augment LR analysis in our hereditary can-
cer panel of 25 genes associated with multiple adult-onsethereditary cancers. Once NGS is established as a standard
method for the accurate detection of LRs, microarrays
may retain utility for confirmatory testing. Panel-based
testing strategies will help identify additional patients with
a hereditary cancer syndrome and enable clinicians to
better manage individuals and families who are affected
or at risk for these inherited disorders with specific
genetic and clinical counseling, screening, and treat-
ment recommendations.
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